Keryx Biopharmaceuticals Inc Sample Contracts

October 1st, 2009 · Common Contracts · 1000 similar
Keryx Biopharmaceuticals IncSECURITIES PURCHASE AGREEMENT

This Securities Purchase Agreement (this “Agreement”) is dated as of September 25, 2009, between Keryx Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

July 21st, 2005 · Common Contracts · 589 similar
Keryx Biopharmaceuticals IncExhibit 1.1 KERYX BIOPHARMACEUTICALS, INC. 5,030,000 Shares of Common Stock, par value $0.001 per share Underwriting Agreement
November 9th, 2016 · Common Contracts · 306 similar
Keryx Biopharmaceuticals IncKERYX BIOPHARMACEUTICALS, INC. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement

Keryx Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:

May 10th, 2018 · Common Contracts · 57 similar
Keryx Biopharmaceuticals IncREGISTRATION RIGHTS AGREEMENT BY AND AMONG KERYX BIOPHARMACEUTICALS, INC. AND BAUPOST GROUP SECURITIES, L.L.C. DATED AS OF MAY 9, 2018

This REGISTRATION RIGHTS AGREEMENT (as it may be amended from time to time in accordance with the terms hereof, the “Agreement”), dated as of May 9, 2018, is made by and among:

May 9th, 2011 · Common Contracts · 51 similar
Keryx Biopharmaceuticals Inc7,021,277 Shares Common Stock ($0.001 par value) Underwriting Agreement

Keryx Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (collectively, the “Underwriters”) for whom Stifel, Nicolaus & Company, Incorporated is acting as representative (the “Representative”), an aggregate of 7,021,277 shares (the “Shares”) of common stock, par value $0.001 per share, of the Company (the “Common Stock”).

November 9th, 2016 · Common Contracts · 36 similar
Keryx Biopharmaceuticals IncINDEMNIFICATION AGREEMENT

This Indemnification Agreement, dated as of [ ] (this “Agreement”), is made by and between Keryx Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and [ ] (“Indemnitee”).

January 27th, 2015 · Common Contracts · 17 similar
Keryx Biopharmaceuticals IncKeryx Biopharmaceuticals, Inc. 9,166,667 Shares Common Stock ($0.001 par value) Underwriting Agreement

Keryx Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (collectively, the “Underwriters”) for whom J.P. Morgan Securities LLC is acting as representative (the “Representative”), an aggregate of 9,166,667 shares (the “Underwritten Shares”) of common stock, par value $0.001 per share, of the Company (the “Common Stock”) and, at the option of the Underwriters, up to an additional 1,375,000 shares of Common Stock (the “Option Shares” and, together with the Underwritten Shares, the “Shares”).

May 10th, 2018 · Common Contracts · 11 similar
Keryx Biopharmaceuticals IncKERYX BIOPHARMACEUTICALS, INC. ZERO COUPON CONVERTIBLE SENIOR NOTES DUE 2021 INDENTURE DATED AS OF MAY 9, 2018 THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., AS TRUSTEE

INDENTURE, dated as of May 9, 2018, between KERYX BIOPHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., a national banking association, as Trustee (the “Trustee”).

December 12th, 2003 · Common Contracts · 10 similar
Keryx Biopharmaceuticals IncExhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this "Agreement") is made and entered into as of November 12, 2003, among Keryx Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and the purchasers'...
February 21st, 2018 · Common Contracts · 8 similar
Keryx Biopharmaceuticals IncEMPLOYMENT AGREEMENT BETWEEN GREGORY P. MADISON AND

THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into this 10th day of March, 2015 by and between Keryx Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and Gregory P. Madison (“Executive”), to be effective as of the Effective Date, as defined in Section 1.

August 14th, 2002 · Common Contracts · 6 similar
Keryx Biopharmaceuticals IncExhibit 10.2 AMENDED EMPLOYMENT AGREEMENT This employment agreement (the "Agreement") is effective as of November 26, 2001(the "Effective Date"), by and between Keryx (Israel) Ltd., an Israeli company with it principal place of business at 7 Hartom...
May 10th, 2018 · Common Contracts · 5 similar
Keryx Biopharmaceuticals IncAMENDED & RESTATED LICENSE AGREEMENT

THIS AMENDED & RESTATED LICENSE AGREEMENT (the “Agreement”), effective as of this 17th day of March, 2008 (the “Effective Date”), by and between Panion & BF Biotech, Inc., with offices at 16F No. 3, Yuanqu Street, Nangang District, Taipei, Taiwan, ROC (hereinafter "Licensor"), and Keryx Biopharmaceuticals, Inc, with offices at 750 Lexington, 20th Floor, New York, NY 10022 (hereinafter "Licensee").

March 30th, 2006 · Common Contracts · 5 similar
Keryx Biopharmaceuticals IncSECURITIES PURCHASE AGREEMENT

THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of the 24th day of March, 2006, by and among Keryx Biopharmaceuticals, Inc., a Delaware corporation (the “Company”) and the purchaser executing the purchase signature page attached hereto (the “Purchaser”); and

November 7th, 2017 · Common Contracts · 4 similar
Keryx Biopharmaceuticals IncAMENDED AND RESTATED SUBLICENSE AGREEMENT

THIS AMENDED AND RESTATED SUBLICENSE AGREEMENT (the “Agreement”), effective this 8th day of June, 2009 (the “Effective Date”), by and between KERYX BIOPHARMACEUTICALS, INC., with offices at 750 Lexington Avenue, 20th Floor, New York, NY 10022, U.S.A. (“Keryx” or “Sublicensor”) and JAPAN TOBACCO INC., with offices at JT Building, 2-1, Toranomon 2-Chome, Minato-ku, Tokyo 105-8422, Japan (“JT”) and TORII PHARMACEUTICAL CO., LTD., with offices at Torii Nihonbashi Bldg., 4-1, Nihonbashi-Honcho 3-chome, Chuo-ku, Tokyo 103-8439, Japan (“TORII”) (JT and TORII collectively referred to herein as “Sublicensee”);

July 24th, 2000 · Common Contracts · 4 similar
Keryx Biophamaeuticals IncSCIENTIFIC ADVISORY BOARD AGREEMENT
October 29th, 2015 · Common Contracts · 4 similar
Keryx Biopharmaceuticals IncAMENDMENT ONE TO EMPLOYMENT AGREEMENT

This Amendment Number One (the “Amendment”) to the Employment Agreement dated April 22, 2015 (the “Agreement”) is made and entered into this 15th day of October, 2015 by and between Keryx Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and John F. Neylan, MD (“Executive”), to be effective immediately.

March 1st, 2017 · Common Contracts · 4 similar
Keryx Biopharmaceuticals IncMaster Manufacturing Services Agreement September 27, 2016

THIS AGREEMENT WITNESSES THAT in consideration of the rights conferred and the obligations assumed herein, and for other good and valuable consideration (the receipt and sufficiency of which are acknowledged by each party), and intending to be legally bound the parties agree as follows:

August 9th, 2018 · Common Contracts · 3 similar
Keryx Biopharmaceuticals IncKERYX BIOPHARMACEUTICALS, INC. RETENTION BONUS AWARD AGREEMENT

This Retention Bonus Award Agreement (this “Agreement”) is made and entered into on May 1, 2018 (the “Effective Date”), between Keryx Biopharmaceuticals, Inc. (the “Company”) and John F. Neylan, M.D. (“Employee”).

May 19th, 2000 · Common Contracts · 3 similar
Keryx Biophamaeuticals IncAGREEMENT ---------
July 24th, 2000 · Common Contracts · 3 similar
Keryx Biophamaeuticals IncEXHIBIT 10.13 MANAGEMENT SERVICES AGREEMENT THIS MANAGEMENT SERVICES AGREEMENT is made as of the 30th day of November, 1999 by and between Lakaro Biopharmaceuticals, Inc., a Delaware corporation (the "Sponsor") and B.R.T. Biopharmaceuticals Ltd. (the...
July 24th, 2000 · Common Contracts · 2 similar
Keryx Biophamaeuticals IncEXHIBIT 10.19 TENANCY AGREEMENT
October 1st, 2018 · Common Contracts · 2 similar
Keryx Biopharmaceuticals IncFIRST AMENDMENT TO AGREEMENT AND PLAN OF MERGER

This FIRST AMENDMENT TO AGREEMENT AND PLAN OF MERGER (this “Amendment”), dated as of October 1, 2018 is entered into by and among Akebia Therapeutics, Inc., a Delaware corporation (“Akebia”); Alpha Therapeutics Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Akebia (“Merger Sub”); and Keryx Biopharmaceuticals, Inc., a Delaware corporation (“Keryx” and collectively with Akebia and Merger Sub, the “Parties,” and each a “Party”). Capitalized terms used herein and not otherwise defined shall have the same meanings as set forth in the Agreement and Plan of Merger, dated as of June 28, 2018, by and among the Parties (the “Merger Agreement”).

July 24th, 2000 · Common Contracts · 2 similar
Keryx Biophamaeuticals IncEXHIBIT 10.20 MANAGEMENT CONTRACT Drafted and signed in Jerusalem on 13 December 1999 Between: PARK MEIR MANAGEMENT COMPANY LTD. 27 Hamered St., Tel Aviv (in the offices of Isras) (hereinafter "THE COMPANY") And: BRT BIOPHARMACEUTICALS LTD. 216 Jaffa...
March 30th, 2004 · Common Contracts · 2 similar
Keryx Biopharmaceuticals IncSUBLICENSE AGREEMENT

This Sublicense Agreement ("Agreement"), effective as of October 13, 2000 (the "Effective Date") is entered into by and between AOI Pharmaceuticals Inc., a subsidiary of Access Oncology, Inc., a corporation having an office at 730 Fifth Avenue, Ninth Floor, New York, NY 10019 ("AOI") and Procept, Inc. (formerly Pacific Pharmaceuticals, Inc.), a Delaware corporation having an office at 369 Lemon Avenue, Tenth Floor, New York, New York 10017 ("Procept").

July 24th, 2000 · Common Contracts · 2 similar
Keryx Biophamaeuticals IncEXHIBIT 10.15 UNPROTECTED TENANCY AGREEMENT
June 28th, 2018 · Common Contracts · 2 similar
Keryx Biopharmaceuticals IncVOTING AGREEMENT

THIS VOTING AGREEMENT (this “Agreement”) is made and entered into as of June 28, 2018, by and between Akebia Therapeutics, Inc., a Delaware corporation (“Akebia”), and the undersigned stockholder (the “Stockholder”) of Keryx Biopharmaceuticals, Inc., a Delaware corporation (“Keryx”).

March 26th, 2002 · Common Contracts · 2 similar
Keryx Biopharmaceuticals IncExhibit 10.29 EMPLOYMENT AGREEMENT This Agreement by and between Keryx Biopharmaceuticals, Inc. ("Keryx"), a Delaware corporation having an address at 101 Main Street, Cambridge, Massachusetts 02142 and Barry Cohen, an individual residing at 38 King...
March 30th, 2004 · Common Contracts · 2 similar
Keryx Biopharmaceuticals IncOMITTED INFORMATION IS THE SUBJECT OF A REQUEST FOR CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

WHEREAS, AOI and Zentaris have entered into a License Agreement for Perifosine dated September 18, 2002 regarding the development, manufacturing and commercialization of Perifosine ("License Agreement"). This addendum is made to define the agreement of the Parties with respect to the Pharmaceutical Development of Perifosine API and Perifosine Drug Product.

July 24th, 2000 · Common Contracts · 2 similar
Keryx Biophamaeuticals IncEXHIBIT 10.9 RESEARCH AGREEMENT ------------------ This Research Agreement (the "Agreement") is made as of this 18th day of November, 1999 by and between YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, 46 Jabotinsky Street,...
July 24th, 2000 · Common Contracts · 2 similar
Keryx Biophamaeuticals IncEXHIBIT 10.7 LICENSE AGREEMENT
July 24th, 2000 · Common Contracts · 2 similar
Keryx Biophamaeuticals IncExhibit 10.21 FORM OF SCIENTIFIC ADVISORY BOARD AND CONSULTANT AGREEMENT
July 24th, 2000 · Common Contracts · 2 similar
Keryx Biophamaeuticals IncEXHIBIT 10.14 FINDER AGREEMENT ---------------- Pursuant to this Finder Agreement (this "Agreement") entered into November 19, 1999, (the "Effective Date"), between Lakaro BioPharmaceuticals, Inc., a company organized under the laws of the State of...
August 14th, 2002 · Common Contracts · 2 similar
Keryx Biopharmaceuticals IncExhibit 10.1 EMPLOYMENT AGREEMENT This Agreement, dated as of November 26, 2001, by and between Keryx Biopharmaceuticals, Inc. ("Keryx"), a Delaware corporation having an address at 101 Main Street, Cambridge, Massachusetts, United States of America,...
March 16th, 2004 · Common Contracts · 2 similar
Keryx Biopharmaceuticals IncExhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this "Agreement") is made and entered into as of February 17, 2004, among Keryx Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and the purchasers'...
March 30th, 2004
Keryx Biopharmaceuticals IncLicense and Cooperation Agreement FOR PERIFOSINE by and between Zentaris AG Weismüllerstr. 45 60314 Frankfurt am Main Germany - herein "Zentaris" - and AOI Pharma, Inc. 750 Lexington Avenue, 26th Floor New York, New York 10022 USA - herein "AOI" -

Whereas, AOI desires to obtain certain licenses from Zentaris to develop and commercialize Perifosine under the aforesaid patents and know-how, and Zentaris is willing to grant to AOI such licenses;